Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.41 |
| ▸ | CTSS | P25774 | 12/20 | 0.41 |
| ▸ | CTSL | P07711 | 9/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | ITK | Q08881 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3166074 | 0.94 | CTSS (0.38) | CTSKCTSSCTSLCTSB | |
| SCHEMBL3173740 | 0.91 | CTSK (0.47) | CTSKCTSSCTSLCTSBITK | |
| SCHEMBL3176722 | 0.90 | CTSK (0.43) | CTSKCTSSCTSLCTSBITK | |
| SCHEMBL3173592 | 0.90 | ITK (0.43) | CTSKCTSSCTSLCTSBITK | |
| SCHEMBL3169251 | 0.89 | CTSK (0.42) | CTSKCTSSCTSLCTSBITK | |
| SCHEMBL3175962 | 0.88 | CTSL (0.43) | CTSKCTSSCTSLCTSBITK | |
| SCHEMBL3169544 | 0.87 | CTSS (0.43) | CTSKCTSSCTSLCTSBITK | |
| SCHEMBL3168819 | 0.87 | CTSK (0.42) | CTSKCTSSCTSLCTSBITK | |
| SCHEMBL3165496 | 0.87 | CTSK (0.46) | CTSKCTSSCTSLCTSBITK | |
| SCHEMBL8206083 | 0.87 | MEN1 (0.35) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | claimed |
| EP-2030621-A1 | Novel substituted pyrimidines as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | disclosed |
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | disclosed |
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | Glaxo Group Limited , a corporation | 2010-01-14 | — | — | US | disclosed |
| EP-2030621-A1 | Novel substituted pyrimidines as cysteine protease inhibitors | GLAXO GROUP LIMITED (GB) | 2009-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009956-A1 | NOVEL SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS | SERPINB1, CTRL, PRSS1 | CTSK 65/4885CTSS 15/4885CTSL 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.